Cefepime-Taniborbactam Superior to Meropenem for Complicated UTI
By Elana Gotkine HealthDay Reporter
THURSDAY, Feb. 15, 2024 -- For adults with complicated urinary tract infection (UTI), including acute pyelonephritis, cefepime-taniborbactam is superior to meropenem, according to a study published in the Feb. 15 issue of the New England Journal of Medicine.
Florian M. Wagenlehner, M.D., from Justus Liebig University in Giessen, Germany, and colleagues conducted a phase 3 randomized trial involving hospitalized adults with complicated UTI, including acute pyelonephritis. Participants were randomly assigned to receive intravenous cefepime-taniborbactam (2.5 g) or meropenem (1 g) every eight hours for seven days in a 2:1 ratio; in the case of bacteremia, this duration could be extended up to 14 days.
The researchers found that composite success (microbiologic and clinical success on trial days 19 to 23) occurred in 70.6 and 58.0 percent of patients in the cefepime-taniborbactam and meropenem groups, respectively, with cefepime-taniborbactam superior to meropenem (treatment difference, 12.6 percentage points). At late follow-up (days 28 to 35), differences in treatment response were sustained, with higher composite success and clinical success seen for cefepime-taniborbactam. Adverse events occurred in 35.5 and 29.0 percent of patients in the cefepime-taniborbactam and meropenem groups, respectively; the two groups had a similar frequency of serious adverse events.
"Cefepime-taniborbactam was shown to be a potential treatment option for patients with complicated UTI and acute pyelonephritis caused by Enterobacterales species and P. aeruginosa, including antimicrobial-resistant strains," the authors write.
The study was funded by VenatoRx Pharmaceuticals, the developer of cefepime-taniborbactam.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
FDA Approves New Antibiotic, Pivya, for Uncomplicated Urinary Tract Infections
TUESDAY, April 30, 2024 -- The U.S. Food and Drug Administration has approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract...
Computer Prompts Could Reduce Empiric Antibiotic Use for UTI
FRIDAY, April 19, 2024 -- For non-critically ill patients with urinary tract infection (UTI), computerized provider order entry (CPOE) prompts providing patient- and...
Obstructive Sleep Apnea Linked to Bladder Pain/Interstitial Cystitis
THURSDAY, March 7, 2024 -- Obstructive sleep apnea (OSA) seems to be associated with bladder pain syndrome/interstitial cystitis (BPS/IC) in women, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.